Project title: Treating neuroendocrine tumors via synthetic lethality

Michael German, MD University of California, San Francisco, San Francisco, CA

Michael German, MD
  • Status: Completed
  • Year(s): 2014
  • Grant Type: Investigator
  • Research Type: Translational
  • Primary Site: Pancreas
  • Area of Inquiry: Signaling/drug targets

General Description

To test an FDA approved inhibitor of Mek1/2 (FDA approved for melanoma) in preclinical models of neuroendocrine tumors. The results will provide insight into the unique mechanisms that drive neuroendocrine cancer growth. Positive results of an already approved drug could speed the path from the bench-to-bedside to pave the way for clinical trials.

Publication

Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.

Additional Details

  • City: San Francisco
  • Grant Duration: 2 years
  • Grant Partner: American Association for Cancer Research (AACR)
« Back to all funded research projects